Last reviewed · How we verify
NCT02692157: NT-814
NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study
Phase 1/Phase 2 trial testing Placebo in Opioid Use Disorder. Withdrawn.
20 July 2017
Quick facts
| Lead sponsor | New York State Psychiatric Institute |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Start date | 1 February 2016 |
| Primary completion | 20 July 2017 |
| Estimated completion | 20 September 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Placebo
- NT-814 50 mg — full drug profile →
- NT-814 100 mg — full drug profile →
- NT-814 200 mg — full drug profile →
Conditions studied
- Opioid Use Disorder — all drugs for Opioid Use Disorder →
Sponsor
New York State Psychiatric Institute
Who can join
Adults 21 to 59, male only, with Opioid Use Disorder. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Percentage of oxycodone choices
Time frame: 1 week
Percentage of drug (versus money) choices in each study arm will be our primary outcome measure. -
Average visual analog scale ratings of "I like the choice"
Time frame: 1 week
Average ratings of oxycodone liking in each study arm will be obtained.
Sponsor's own description
Healthy adult men who abuse opioids and are physically dependent on them will be invited to participate in a study to examine the ability of NT-814, a neurokinin (NK) antagonist at the 1 and 3 receptor subtypes, to alter the abuse liability of oxycodone.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evidence of heterogeneity in the opioid withdrawal syndrome: Spontaneous and precipitated withdrawal.
Martinez S, Jones JD, Dunn KE, Huhn A, et al · · 2026 · PMID 41520950 · DOI 10.1016/j.pbb.2026.174153
Verify or expand the search:
- PubMed search for NCT02692157
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid Use Disorder
Currently open trials in the same condition.
- NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
- NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
- NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
Other New York State Psychiatric Institute trials
Trials by the same sponsor.
- NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
- NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
- NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
- NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
- NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02692157 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
- Last refreshed: 31 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02692157.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing